Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Although not the most prevalent comorbid condition in patients with T2DM, heart failure was the most fatal in a 17-year long nationwide real-life cohort study.
Read More »Heart Failure in T2DM: Ready for Prime Time?
Managing Editor, Diabetes in Control
COVID-19 Severity Perceived in Recently Diagnosed Diabetes Patients
Newly-diagnosed diabetes and admission hyperglycemia are linked to rapid respiratory deterioration in COVID-19 patients.
Read More »PRE-D Trial: Effect of Metformin, Dapagliflozin, or Exercise on Prediabetes Outcomes
Multiple treatments were compared to improve outcomes in patients with prediabetes.
Read More »Targeting Postprandial Glucose as it Relates to A1C and Cardiovascular Disease
The future of measuring and controlling postprandial glucose using TIR (Time in Range).
Read More »Lilly & Dexcom Diabetes Management Partnership: Diabetes in Control Interview
Technology and unique rapid-acting insulin can improve time in range and Quality of Life for patients with diabetes.
Read More »Optimal Treatment In T2D For CV Protection
How triple therapy can lead to optimal cardiovascular and renal protection.
Read More »Weekly Semaglutide vs. Daily Sitagliptin in T2D Patients
One diabetes drug showed superior results for A1C reduction and weight loss.
Read More »Bone Density Mass in Youth with Type 2 Diabetes
What is the impact of type 2 diabetes on bone formation in maturing bodies?
Read More »Telemedicine For Management of Diabetes Amid COVID-19 Concerns: Does It Work?
Patients are relieved to know that care continues through the coronavirus pandemic.
Read More »The Benefits of Exenatide From the EXSCEL Study
The EXSCEL trial may not have shown that once-weekly exenatide had cardiovascular benefits for patients with diabetes, but did show a benefit in some significant areas.
Read More »